Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors

Histone deacetylases (HDACs) and sirtuins (SIRTs) are important epigenetic regulators of cancer pathways. There is a limited understanding of how transcriptional regulation of their genes is affected by chemotherapeutic agents, and how such transcriptional changes affect tumour sensitivity to drug t...

Full description

Saved in:
Bibliographic Details
Main Authors: Julia Krushkal, Yingdong Zhao, Kyle Roney, Weimin Zhu, Alan Brooks, Deborah Wilsker, Ralph E. Parchment, Lisa M. McShane, James H. Doroshow
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Epigenetics
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/15592294.2024.2309824
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850138015043682304
author Julia Krushkal
Yingdong Zhao
Kyle Roney
Weimin Zhu
Alan Brooks
Deborah Wilsker
Ralph E. Parchment
Lisa M. McShane
James H. Doroshow
author_facet Julia Krushkal
Yingdong Zhao
Kyle Roney
Weimin Zhu
Alan Brooks
Deborah Wilsker
Ralph E. Parchment
Lisa M. McShane
James H. Doroshow
author_sort Julia Krushkal
collection DOAJ
description Histone deacetylases (HDACs) and sirtuins (SIRTs) are important epigenetic regulators of cancer pathways. There is a limited understanding of how transcriptional regulation of their genes is affected by chemotherapeutic agents, and how such transcriptional changes affect tumour sensitivity to drug treatment. We investigated the concerted transcriptional response of HDAC and SIRT genes to 15 approved antitumor agents in the NCI-60 cancer cell line panel. Antitumor agents with diverse mechanisms of action induced upregulation or downregulation of multiple HDAC and SIRT genes. HDAC5 was upregulated by dasatinib and erlotinib in the majority of the cell lines. Tumour cell line sensitivity to kinase inhibitors was associated with upregulation of HDAC5, HDAC1, and several SIRT genes. We confirmed changes in HDAC and SIRT expression in independent datasets. We also experimentally validated the upregulation of HDAC5 mRNA and protein expression by dasatinib in the highly sensitive IGROV1 cell line. HDAC5 was not upregulated in the UACC-257 cell line resistant to dasatinib. The effects of cancer drug treatment on expression of HDAC and SIRT genes may influence chemosensitivity and may need to be considered during chemotherapy.
format Article
id doaj-art-76cdf0bfff0e453b87e8b5bd10e9b649
institution OA Journals
issn 1559-2294
1559-2308
language English
publishDate 2024-12-01
publisher Taylor & Francis Group
record_format Article
series Epigenetics
spelling doaj-art-76cdf0bfff0e453b87e8b5bd10e9b6492025-08-20T02:30:41ZengTaylor & Francis GroupEpigenetics1559-22941559-23082024-12-0119110.1080/15592294.2024.2309824Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitorsJulia Krushkal0Yingdong Zhao1Kyle Roney2Weimin Zhu3Alan Brooks4Deborah Wilsker5Ralph E. Parchment6Lisa M. McShane7James H. Doroshow8Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USABiometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USADepartment of Biostatistics and Bioinformatics, George Washington University, Washington, DC, USAClinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USAClinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USAClinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USAClinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USABiometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USADivision of Cancer Treatment and Diagnosis and Center for Cancer Research, National Cancer Institute, Bethesda, MD, USAHistone deacetylases (HDACs) and sirtuins (SIRTs) are important epigenetic regulators of cancer pathways. There is a limited understanding of how transcriptional regulation of their genes is affected by chemotherapeutic agents, and how such transcriptional changes affect tumour sensitivity to drug treatment. We investigated the concerted transcriptional response of HDAC and SIRT genes to 15 approved antitumor agents in the NCI-60 cancer cell line panel. Antitumor agents with diverse mechanisms of action induced upregulation or downregulation of multiple HDAC and SIRT genes. HDAC5 was upregulated by dasatinib and erlotinib in the majority of the cell lines. Tumour cell line sensitivity to kinase inhibitors was associated with upregulation of HDAC5, HDAC1, and several SIRT genes. We confirmed changes in HDAC and SIRT expression in independent datasets. We also experimentally validated the upregulation of HDAC5 mRNA and protein expression by dasatinib in the highly sensitive IGROV1 cell line. HDAC5 was not upregulated in the UACC-257 cell line resistant to dasatinib. The effects of cancer drug treatment on expression of HDAC and SIRT genes may influence chemosensitivity and may need to be considered during chemotherapy.https://www.tandfonline.com/doi/10.1080/15592294.2024.2309824Histone deacetylasesirtuindasatinibchemosensitivityHDAC5
spellingShingle Julia Krushkal
Yingdong Zhao
Kyle Roney
Weimin Zhu
Alan Brooks
Deborah Wilsker
Ralph E. Parchment
Lisa M. McShane
James H. Doroshow
Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors
Epigenetics
Histone deacetylase
sirtuin
dasatinib
chemosensitivity
HDAC5
title Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors
title_full Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors
title_fullStr Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors
title_full_unstemmed Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors
title_short Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors
title_sort association of changes in expression of hdac and sirt genes after drug treatment with cancer cell line sensitivity to kinase inhibitors
topic Histone deacetylase
sirtuin
dasatinib
chemosensitivity
HDAC5
url https://www.tandfonline.com/doi/10.1080/15592294.2024.2309824
work_keys_str_mv AT juliakrushkal associationofchangesinexpressionofhdacandsirtgenesafterdrugtreatmentwithcancercelllinesensitivitytokinaseinhibitors
AT yingdongzhao associationofchangesinexpressionofhdacandsirtgenesafterdrugtreatmentwithcancercelllinesensitivitytokinaseinhibitors
AT kyleroney associationofchangesinexpressionofhdacandsirtgenesafterdrugtreatmentwithcancercelllinesensitivitytokinaseinhibitors
AT weiminzhu associationofchangesinexpressionofhdacandsirtgenesafterdrugtreatmentwithcancercelllinesensitivitytokinaseinhibitors
AT alanbrooks associationofchangesinexpressionofhdacandsirtgenesafterdrugtreatmentwithcancercelllinesensitivitytokinaseinhibitors
AT deborahwilsker associationofchangesinexpressionofhdacandsirtgenesafterdrugtreatmentwithcancercelllinesensitivitytokinaseinhibitors
AT ralpheparchment associationofchangesinexpressionofhdacandsirtgenesafterdrugtreatmentwithcancercelllinesensitivitytokinaseinhibitors
AT lisammcshane associationofchangesinexpressionofhdacandsirtgenesafterdrugtreatmentwithcancercelllinesensitivitytokinaseinhibitors
AT jameshdoroshow associationofchangesinexpressionofhdacandsirtgenesafterdrugtreatmentwithcancercelllinesensitivitytokinaseinhibitors